Navigation Links
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
Date:12/3/2008

at ASH include:

  • Tasigna data showing its benefit in the first-line treatment setting for patients with chronic myeloid leukemia, in two oral presentations (ASH Abstracts #181 & 446; Monday, December 8, 2008; 7:00 AM PST & 1:45 PM PST, respectively)
  • Cardiac data from the landmark EPIC trial, demonstrating significant benefit with Exjade in patients with transfusion-dependent anemias (ASH Abstract #3873; Monday, December 8, 2008; 5:30 PM PST). More than ten additional abstracts from the EPIC trial in patients with different underlying anemias will also be presented
  • RAD001 data demonstrating benefit in patients with relapsed and/or refractory Waldenstrom Macroglobulinemia(ASH Abstract #1011; Saturday, December 6, 2008; 5:30 - 7:30 PM PST)
  • More than 10 abstracts on panobinostat (LBH589), showing early activity across a broad range of cancers, including acute myeloid leukemia, cutaneous t-cell lymphoma, multiple myeloma and mantle cell lymphoma

The most significant presentations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) will include:

  • New data, presented in an oral session, from major international BIG 1-98 trial evaluating Femara vs. tamoxifen and the sequencing of the two therapies show evidence of optimal treatment strategy for postmenopausal women with breast cancer (SABCS Abstract #13; Thursday, December 11, 2008; 9:45 - 10:00 AM CST)
  • The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct anti-tumor activity in breast cancer (AZURE subgroup analysis) (SABCS Abstract #5101; Saturday, December 13, 2008; 5:00 - 7:00 PM CST). A total of nine Z
    '/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
5. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
6. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. New Conflict of Interest Violations Revealed at California Stem Cell Institute
9. St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia
10. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) today ... ended June 30, 2015 and updated its financial guidance ... call this morning, August 4, 2015, at 10:30 AM ... call by dialing (855) 582-8078. The conference ID is ... net revenues of $38.3 million, an increase of 118% as ...
(Date:8/3/2015)... Ill. , Aug. 3, 2015  Landauer, Inc. ... and environmental radiation measurement and monitoring, outsourced medical physics ... it will release financial results for the fiscal third ... 10, 2015. The Company will also ... 11, 2015 at 9:00 a.m. Central Time (10:00 a.m. ...
(Date:8/3/2015)... Calif., Aug. 3, 2015  DURECT Corporation (Nasdaq: DRRX ... 2015.  Total revenues were $4.4 million and net loss was ... as compared to total revenues of $4.6 million and net ... 30, 2014.At June 30, 2015, we had cash and investments ... million at December 31, 2014.  At June 30, 2015, we ...
Breaking Medicine Technology:ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 4ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 5ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 6ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 7ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 8ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 9ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 10ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 11ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 12ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 13ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 14ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 15ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 16Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10
... NEW YORK, Oct. 19, 2011 Reportlinker.com ... is available in its catalogue: ... Prospects ... of patients to monitor their own serum ...
... Ill., Oct. 18, 2011 Researchers found Chicago area ... and its effects when they first use it, and ... pain medications. Those are some of the ... Use," for the Robert Crown Center for Health Education,s ...
Cached Medicine Technology:Patient Self-Monitoring: Devices, Markets, Players and Prospects 2Patient Self-Monitoring: Devices, Markets, Players and Prospects 3Study Sheds Light on Young Suburban Heroin Users 2
(Date:8/4/2015)... Hills, CA (PRWEB) , ... August 04, 2015 ... ... personal consultation complete with full examination now offered by the world renowned ... more beautiful aesthetic facial appearance through cosmetic surgery techniques helps individuals to achieve ...
(Date:8/4/2015)... ... August 04, 2015 , ... Providigm, LLC, ... care facilities, today announced details of the Advanced level of their national accreditation ... Providigm’s QAPI Accreditation program , introduced in 2013, is based on standards ...
(Date:8/4/2015)... D.C. (PRWEB) , ... August ... ... that its HealthCenter personal health record (PHR) product has achieved Office of ... and Inpatient EHR Certification from Drummond Group. HealthCenter delivers the highest quality ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... and Scale-up Online Seminar featuring researchers from Lubrizol, Pfizer, and Merck. ... PM EDT. , Process development project timelines often require informed decisions with limited ...
(Date:8/4/2015)... ... ... The results of a three year clinical trial for the Argus II, ... causes blindness, were published on June 23, 2015 in Ophthalmology , the journal ... implant, more commonly known as the “bionic eye,” is safe and effective for long-term ...
Breaking Medicine News(10 mins):Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2
... A small study suggests that adults whose parents are ... have lower average levels of the stress hormone cortisol ... to a report in the September issue of Archives ... Biological differences seen in individuals with PTSD, including low ...
... nonprofit patient advocacy group, today released updated resources,to help ... back to,school. The organization offers a free fact sheet ... and deliver to their child,s school,teacher; and it offers ... how to treat psoriasis in children and how to ...
... , , MONDAY, Sept. 3 (HealthDay News) --The more hours adults ... job, the less time they spend sleeping. , That,s the ... on slumber. , Adults who sleep four-and-a-half hours or fewer ... 118 minutes more on weekends than the average sleeper, a ...
... LES ULIS, France, September 3 - QUANTEL ... in View,of Acquiring the Company WaveLight Aesthetic GmbH ... the German company WaveLight AG, is,specialized in Dermatology/Aesthetic lasers. ... its revenues are estimated of approx. 10MEUR,for the fiscal ...
... Cambridge, famous as a haunt of students in their ... next generation of antibiotics, according to scientists speaking today ... Microbiologys 161st Meeting at the University of Edinburgh, UK, ... now over-prescribed for treatments of bacterial infections, and patients ...
... Lexington, KY (Aug. 31, 2007) Two worldwide studies published ... growth rate of chronic obstructive pulmonary disease (COPD). The only ... Study was located in Eastern Kentucky, and was found to ... world. In fact, it had the second highest rate ...
Cached Medicine News:Health News:Adult offspring of parents with PTSD have lower cortisol levels 2Health News:Psoriasis Cure Now offers 'Back to School' Resources for Parents of Children with Psoriasis 2Health News:Work Time Predicts Sleep Time 2Health News:QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH 2Health News:New viruses to treat bacterial diseases -- 'My enemies' enemy is my friend' 2Health News:Two studies published in the Lancet 2
Mid-level interpretive resting ECG...
... The ECG-9010 meets IEC60601-2-51 new international ... and digital filter performance. ECG data ... a Windows PC with the optional ... changed for operating in other countries, ...
The Sonic WAVE™is the first market-ready Alternative to Ultrasound...
... is an innovative, stat analyzer that measures ... on-board co-oximetry and integrated data management "all ... include pH, PCO 2 , PO 2 ... sodium, potassium, chloride, ionized calcium, ionized magnesium, ...
Medicine Products: